The Epicholesteryl Betulinate and the Pegylated 3’ α-Cholesteryl Betulinate are Active Against Liver Carcinoma. A Case Study.

E. Couché 1, M. Gelbcke 2, A. Burny 3 and J.C. Leunis 4,*

1Ecole Européenne de Luxembourg, Bv Konrad Adenauer 23, L-1115 Luxembourg
2Faculty of Pharmacy, ULB, Free University of Brussels
3Molecular and Cellular Biology, University of Liège
4Jean Monnet Research Center - 1, Jean Monnet Avenue B - 1348, Louvain-la-Neuve

*Corresponding author: J.C. Leunis, Jean Monnet Research Center - 1, Jean Monnet Avenue B - 1348, Louvain-la-Neuve; Tel: +00-32-10-810 460; E-mail: jleunis@hotmail.com

Introduction

The potential value of triterpenoids, especially pentacyclic triterpenes like betulin, betulinic acid and betulonic acid in the induction of apoptosis in malignant tumor cells has been recognized for some years now [1,2].

Betulinic acid (BetA) and betulin come from a variety of botanical sources such as the bark from Betulaceae like Betulae species, Alnus glutinosa, Corulus avellana Carpinus betulus, as well as Platanaceae like Platanus orientalis and from Rhamnaceae like Ziziphus species [3,4]. BetA and betulonic acid are thus found in many plant species, although in a low concentration compared to betulin [5]. Betulinic acid (BetA) induces apoptosis of many types of cancer cells without toxicity towards normal cells in vitro and in vivo [6].
Methods of synthesis of many derivatives of BetA and betulonic acid have been described, including amino acid, amide as well as glycosides derivatives [7,8]. Several patents on BetA analogs for the chemotherapy of cancer have been reported. Most of these patents deal with modifications at positions C-3, C-20, and C-28 [9].

In this study, we tested the anti liver carcinoma activity of two cholesteryl ester derivatives of betulinic acid in C-28: the epicholesteryl betulinate is oil-soluble and its pegylated form is water-soluble [10].

**Why cholesterol as cancer recognized epitope?**

Cancer cells proliferate rapidly and require high cholesterol concentration [11].

Mullauer FB et al described that betulin, here the lesser active of the three triterpenes, is a potent anti-tumor agent that is enhanced by cholesterol [12].

Cholesterol is indeed essential for the development of the cell membrane and it is found in the lipid rafts of all our cells.

It is, therefore, an essential nutrient for the cancer cell.

The antitumor pharmacological effects consist of triggering apoptosis via the mitochondrial pathway, regulating the cell cycle and the angiogenic pathway via a variety of factors, including different transcription factors [13].

**A case study**

The alcoholic patient, B.H. born 06 April 1956, suffering from liver cancer developed on cirrhosis was, the 24 of Dec.2015, considered as lost for the medicine.

During hospitalization in December 2015, decompensated cirrhosis on hepatocarcinoma with the presence of ascites was diagnosed with the invasion of the portal vein.

The abdominal CT scan performed showed a 12 cm hepatocarcinoma in the right lobe.

Given the lack of therapy, the patient, Dr. in veterinary medicine, refused palliative care and decided on an experimental treatment by oral intake of two derivatives of betulinic acid. The Epicholesteryl betulinate and the Pegylated 3’ a-cholesteryl betulinate.

---

**Figure 1: Structure of the natural active compounds**

Methods of synthesis of many derivatives of BetA and betulonic acid have been described, including amino acid, amide as well as glycosides derivatives [7,8]. Several patents on BetA analogs for the chemotherapy of cancer have been reported. Most of these patents deal with modifications at positions C-3, C-20, and C-28 [9].

In this study, we tested the anti liver carcinoma activity of two cholesteryl ester derivatives of betulinic acid in C-28: the epicholesteryl betulinate is oil-soluble and its pegylated form is water-soluble [10].

**Why cholesterol as cancer recognized epitope?**

Cancer cells proliferate rapidly and require high cholesterol concentration [11].

Mullauer FB et al described that betulin, here the lesser active of the three triterpenes, is a potent anti-tumor agent that is enhanced by cholesterol [12].

Cholesterol is indeed essential for the development of the cell membrane and it is found in the lipid rafts of all our cells.

It is, therefore, an essential nutrient for the cancer cell.

The antitumor pharmacological effects consist of triggering apoptosis via the mitochondrial pathway, regulating the cell cycle and the angiogenic pathway via a variety of factors, including different transcription factors [13].

**A case study**

The alcoholic patient, B.H. born 06 April 1956, suffering from liver cancer developed on cirrhosis was, the 24 of Dec.2015, considered as lost for the medicine.

During hospitalization in December 2015, decompensated cirrhosis on hepatocarcinoma with the presence of ascites was diagnosed with the invasion of the portal vein.

The abdominal CT scan performed showed a 12 cm hepatocarcinoma in the right lobe.

Given the lack of therapy, the patient, Dr. in veterinary medicine, refused palliative care and decided on an experimental treatment by oral intake of two derivatives of betulinic acid. The Epicholesteryl betulinate and the Pegylated 3’ a-cholesteryl betulinate.
Structure of the two derivatives used in this case study

**Figure 2:** The Epicholesteryl betulinate

**Figure 3:** The pegylated 3’α-cholesteryl betulinate

The synthesis of those derivatives is described in the patents [7].
On the Monday 28.12.15 his alpha-fetoprotein (AFP) level was at 32258 ng/ml and the D-dimers at 16658 ng/ml.

During January 2016, he took per os the cholesteryl ester BetA derivative soluble in oil described in the patent. In February, for personal reasons, he took the water-soluble form.

The patient went back to work for a year but due to persistent alcohol abuse, treatment with a single drug [14] and the now well-documented tumor heterogeneity, resistance to treatment appeared, AFP levels reincreased and the patient died in February 2017. According to his caring doctors, the positive impact of the treatment is unquestionable. No negative side effect was observed.

In the following graph, we document the observed values of AFP and D-dimers and their evolution until February 2016.

The normal physiological values for the parameters shown in the graph are as follows:

- Alpha-fetoprotein - AFP : < 8 µg / L
- D-Dimers : < 500 ng / ml
- Neuro sensitive enolase - NSE - here not drawn : < 12 µg / L

Report of the diagnostic finding are show in figure 5.
Report on diagnostic findings on Circulating Tumor Cells (MAINTRAC)

Dear Dr. Leunis,

Many thanks for sending your examination request regarding the detection of circulating tumor cells.

**Diagnosis:** Hepatocellular Carcinoma

The automated microfluorimetric image analysis of the epithelial cell antigen (HEA)-positive cells with visual control (MAINTRAC) from 1 ml EDTA blood resulted in following findings (detection limit is at 10 cells/ml):

<table>
<thead>
<tr>
<th>Examination parameter</th>
<th>In the sample (1ml)</th>
<th>In circulation (5l) (in millions)</th>
<th>In addit. examination % of HEA-pos. cells</th>
<th>Cell fragments</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEA</td>
<td>100</td>
<td>0.5</td>
<td>some</td>
<td></td>
</tr>
</tbody>
</table>

The material you sent for examination could be thoroughly evaluated. We found only a *minimally to slightly increased number of vital tumor cells circulating in the blood*. In addition, there were some specific cell fragments detected. Specific cell fragments occur, for example, after chemotherapy or radiation, or as part of an immune response and indicate damaged cells.

Under the condition of the prediagnosed hepatocellular cancer, there is a high probability that the cells are originating from this tumor. The low cell numbers, possibly is a result of previous therapies that first eliminates the circulating tumor cells.

We would be grateful for more information relating to the time of the diagnosis and therapies possibly applied, so we could better evaluate the results.

The current cell numbers present a basic value, only an increase in cell numbers is relevant for disease progress. You now have a reference point, from which it can be determined if and how the number of these cells changes in response to therapy.

With best regards,
Dr. med. Ulrich Pachmann      Prof. Dr. med. Katharina Pachmann      Dr. med. Matthias Mäurer

Figure 5
References


10. Leunis JC, Couché E EPO 1999139 and US 8,586,569 – 9,303,058 B2


